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Abstract
Background: Osteoporosis has significant impact on healthcare costs and quality of life. Amongst the models for
collaborative disease state management services published internationally, there is sparse evidence regarding the
role of community pharmacists in the provision of osteoporosis care. Hence, the aim of our study was to explore
community pharmacists’ opinions (including the barriers and facilitators) and scope of osteoporosis disease state
management services by community pharmacists in Malaysia, informing a vision for developing these services.
Methods: Semi-structured individual interviews and focus groups discussions were conducted with community
pharmacists from October 2013 to July 2014. Three trained researchers interviewed the participants. Interviews were
recorded and transcribed verbatim. Data were analyzed thematically using an interpretative description approach.
Results: Nineteen community pharmacists with 1–23 years of experience were recruited (in depth interviews:
n = 9; focus group discussions: n = 10). These participants reflected on their experience with osteoporosis-related
enquiries, which included medication counseling, bone density screening and referral of at-risk patients. Key barriers
were the lack of numerous factors: public awareness of osteoporosis, accurate osteoporosis screening tools for
community pharmacists, pharmacists’ knowledge on osteoporosis disease and medications, time to counsel
patients about bone health, collaboration between pharmacists and doctors, and support from the government
and professional body. The pharmacists wanted more continuing education on osteoporosis, osteoporosis
awareness campaigns, a simple, unbiased osteoporosis education material, and inter-professional collaboration
practices with doctors, and pharmacists’ reimbursement for osteoporosis care.
Conclusions: The involvement of community pharmacists in the provision of osteoporosis disease state
management was minimal. Only ad-hoc counseling on osteoporosis prevention was performed by community
pharmacists. Development and trial of collaborative osteoporosis disease state management services in
community pharmacy could be facilitated by training, support and remuneration.
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Background
Osteoporosis is an increasingly important health prob-
lem with significant impact on morbidity, mortality,
quality of life and cost [1]. By the year 2050, almost 50 %
of hip fractures worldwide will occur in Asia, due to the
density of the elderly population in this continent [2]. In
Malaysia, 7.1 % of the population will be aged 65 years
or over by 2021 [3].
Despite an advancement in the diagnosis of osteopor-
osis, publication of clinical practice guidelines, develop-
ment of screening and fracture risk assessment tools,
and interventions to reduce the risk of fractures, only a
minority of men and women with a high fracture risk re-
ceive treatment [4]. This may be due to healthcare pro-
fessionals’ inertia in initiating treatment for osteoporosis,
or their lack of knowledge [5], or a lack of awareness
among the public of osteoporosis [6, 7]. Undermanaged
osteoporosis incurs significant costs to primary and
secondary care [8, 9]. As such, early detection and
treatment of patients at risk are critical. Preventative
measures at the community level are also urgently
needed.
Pharmacists can play an important role in the
provision of osteoporosis disease state management ser-
vices [10]. This includes identifying and managing the
risk factors for osteoporosis, providing counseling on
nutrition, exercise and lifestyle relevant to bone health,
identifying the role of calcium and vitamin D as pre-
ventative and concomitant therapy for those receiving
osteoporosis treatment, discussing the various treat-
ments available with advantages and disadvantages, and
offering counseling to ensure optimum administration
[10]. In addition, community pharmacists can offer bone
density assessments with heel ultrasound [11, 12], or
fracture risk prediction such as FRAX® [13]. This re-
quires a multidisciplinary/inter-professional collaborative
approach. Compared to other healthcare professionals,
community pharmacists are generally in a better position
to provide continuity of care due to their accessibility to
patients [14–16].
A review of literature on osteoporosis disease state
management found that several studies involving
community pharmacists have been conducted in the
United States [11, 12, 15, 17], Canada [13, 18], The
Netherlands [19, 20], Australia [21] and Thailand
[22]. Most published studies in the United States re-
ported on the implementation and outcomes of osteopor-
osis management services in community pharmacies [11,
17]. However, details regarding the development of these
services were sparse. The reported services comprised
osteoporosis screening, counseling and referral to
physicians [12, 15, 17], as well as risk-factor assess-
ment [11]. These studies reported positive outcomes
relating to osteoporosis awareness, prevention and
patients’ medication adherence and referral of high-
risk patients [11, 17]. However the reported outcomes
did not encompass pharmacists’ confidence, accept-
ability and integration into work flow in delivering
the osteoporosis services, but focused more on patients’
satisfaction. Research into the involvement of community
pharmacists is critical to the conceptualization and accept-
ability of novel services.
There are specific challenges in developing disease
state management services in a number of Asian coun-
tries. In Malaysia, patients can obtain their medicines
directly from a doctor’s clinic, instead of having their
prescriptions dispensed in a community pharmacy [23].
As a result, community pharmacists in Malaysia are not
fully utilized for professional services [24]. In developed
countries such as Australia and the United Kingdom,
where medications are solely dispensed by pharmacists,
community pharmacists have a greater impact on the
community, and have more opportunity to provide
disease state management services [25]. Given the pre-
dicted prevalence of osteoporosis in Asia, the deficien-
cies in studies relating to osteoporosis management
services, and the challenges with establishing such ser-
vices, our study aimed to address these gaps. The aim of
our study was to explore the opinions and scopes of
practice of community pharmacists in Malaysia in osteo-




In view of the exploratory nature of the research ques-
tion, qualitative methodology was applied to enable col-
lection of in-depth information to understand and
interpret the personal experiences of community phar-
macists in their interactions with clients, particularly
osteoporosis patients, in their daily practice. These
experiences were drawn on to identify the community
pharmacists’ opinions (including their barriers and fa-
cilitators), and scope of the osteoporosis disease state
management services. We used an interpretative de-
scriptive qualitative approach, and an inductive ana-
lytical approach to “seek understandings of clinical
phenomena that illuminate their characteristics, pat-
terns and structure” [26]. This method of study was
chosen to describe the phenomena from the perspec-
tive of respondents [27]. Our study was reported ac-
cording the the consolidated criteria for reporting
qualitative studies (Appendix 1).
Setting and participants
This study was conducted in Malaysia, a multi-race
country with a dual-sector health-care system compris-
ing public government-subsidized health care and
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private health care, where most medications are dis-
pensed from government hospital pharmacies, private
health care clinics or hospitals, rather than from com-
munity pharmacies [28]. Most independent commu-
nity pharmacies in Malaysia are privately owned by
pharmacists, while chain pharmacies are owned by
corporations.
We included full-time community pharmacists with
a minimum experience of 1 year as a community
pharmacist, and who were able to converse in either
English or Malay. Inclusion of pharmacists with or
without specific experience in managing osteoporosis
enabled exploration of their perceived barriers to
introducing this type of service. Locum pharmacists
(defined as working fewer than 40 h per week) were
excluded. Purposive sampling was used to achieve
maximal variation based on two factors: years of com-
munity experience, and type of practice (as an inde-
pendent pharmacist, or those employed in chain
pharmacies). If self-employed, pharmacists in inde-
pendent pharmacies would have more liberty to deter-
mine the way they practiced, as opposed to
pharmacists employed in chain pharmacies.
An invitation to participate in this study was posted
online via Facebook, LinkedIn and Eventbrite. The ad-
vertisement explained the objective and nature of the
study. Pharmacists who expressed interest to participate
were contacted by email, and their telephone number
were obtained. The participant information sheet detail-
ing the inclusion criteria for participants and re-
searchers’ contact information was emailed to the
respondents. Where feasible, pharmacists were allocated
to one of two focus groups, scheduled in the morning
over a period of 3 weeks at a convenient venue. Focus
group discussions were conducted whenever possible
to generate discussion among the participants through
group dynamics [29]. Those unable to participate in
one of the focus groups were offered an at-work one-
on-one interview. The researcher then arranged the
interview at a mutually-convenient date and time. At
the end of the interviews or focus group discussions,
participants were asked for any contacts they felt
might be suitable, and if these suggested pharmacists
were considered to meet the criteria for purposive
sampling, they were contacted.
Data collection
An interview topic guide (Table 1) was developed based
on literature review, conceptual framework (described
below) and expert opinion. A baseline demographic
form was used to collect data on participants’ age, gen-
der, education background and practice experience. All
focus group discussions were facilitated by PSML or
CJN, with JN in attendance as a note taker. In depth
interviews were performed by PSML, CJN or JN. Discus-
sions and interviews were audio-recorded, supplemented
by note-taking for focus groups. Each in-depth interview
lasted 30–60 min, whereas each focus group discussion
lasted approximately 60 min. No repeat interviews were
carried out.
Theoretical framework
The integrated behavior model (IBM) was used as a con-
ceptual framework to develop the topic guide for this
study and assisted in the interpretation of data. The IBM
proposes that people act on their intentions when they
have the necessary skills and when environmental factors
do not impede performance. As such, behavior can be
influenced through changes in skills, environmental
factors and behavioral intention [30]. Based on the
IBM determinants, community pharmacists’ opinions
toward the provision of osteoporosis disease state
management services can be explored by interviewing
pharmacists about their skills and knowledge relating
to osteoporosis, their opinions about the importance
of these practices and their environmental constraints.
When people have formed appropriate intentions but
are not acting on them, interventions can be devel-
oped to address skills or environmental barriers such
as lack of public demand and lack of government and
society support [31].
Data analysis
Focus group discussions and interviews were transcribed
verbatim for analysis. The transcripts were not returned
to participants for comment or correction. Grammatical
imperfections were retained to reflect the participants’
voices. A thematic analysis approach was used to
analyze the data within the broad categories of
Table 1 Interview topic guide
1. What sort of pharmaceutical services do you provide?
2. Do you think that the provision of pharmaceutical care would
generate more income for you?
3. What do you understand by the term “osteoporosis”?
4. What would an osteoporosis management service in a pharmacy
comprise?
5. In your opinion, how aware do you think the general public is about
osteoporosis?
6. When did you last refer someone with osteoporosis to a doctor?
7. Do you face any difficulty when dealing with people with osteoporosis?
8. What would encourage you to provide osteoporosis disease state
management services?
9. If you were to start providing osteoporosis disease state
management services, what form of support would you require?
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‘barriers’ and ‘facilitators’. Other relevant data relating
to experiences with the provision of services were
presented descriptively [27]. For the thematic analysis,
four researchers initially worked in pairs (JN/CJN and
PSML/LE) and coded two interviews line-by-line to
develop an initial list of nodes. Using NVivo version
10 (QSR International Pty Ltd), this framework was
then used to code the next transcript. Coding dis-
crepancies were resolved by discussion between repre-
sentatives of the pairs until consensus was reached.
The lists of nodes were used as the final coding
framework for the remaining transcripts. New nodes
emerging during coding were added to the list upon
consultation with the research team, and previously-
coded transcripts were checked in terms of retro-
spective fit of these nodes. The lists of nodes were
regrouped into larger categories as themes emerged
from the data. This systematic approach to the ana-
lysis established an audit trail from the transcripts of
raw data through to the final interpretation. Analysis
was undertaken concurrently with data collection to
check for data saturation [32]. Data collection ceased
when thematic data saturation was reached. Data sat-
uration is occurred when no new themes were per-
ceived by the interviewers to emerge between
interviews 16 and 19, and data collection was ceased
following the 19th interview. Data analysis confirmed
coherence of the emergent themes.
Rigor and trustworthiness
Rigor during data collection was enhanced by recruit-
ment of participants with maximal variation within our
inclusion criteria, standardization of the interview ques-
tions (still allowing for adaption to the conversational
flow), and use of trained interviewers. During analysis,
interpretations were discussed between members of the
research team. Involvement of multiple researchers has
been recommended when conducting qualitative re-
search, particularly to assist with data interpretation;
multiple researchers may supplement and contest each
other’s statements, which may enrich and qualify the
analysis [33, 34].
Results
Nineteen community pharmacists (28–54 years of age),
with 1–23 years of experience as community pharma-
cists were recruited. Nine pharmacists underwent in
depth interviews, whilst 10 pharmacists participated
in focus group discussions. The majority were female
(n = 12). All participants had a Bachelor degree in
Pharmacy. Most of the pharmacists recruited (n = 13)
were from independent pharmacies. Findings are pre-
sented in three sections: description of osteoporosis
disease state management services components
followed by the barriers and facilitators to this ser-
vice. The quantification of nodes for each themes was
presented in Appendix 2 to present the relative em-
phasis given by community pharmacists.
Provision of osteoporosis disease state management
services by community pharmacists
In this study, most community pharmacists did not pro-
actively provide osteoporosis disease state management
services. However, 13 pharmacists (10 from independent,
3 from chain pharmacies) reported receiving and
responding to requests for information from patients
about the risk factors for osteoporosis and preventa-
tive measures, and providing advice on weight-
bearing exercise. Recognized risk factors were smok-
ing, those who drink excessive amounts of alcohol
and caffeine, those who are thin and small built, and
use of medicines such as steroids or thyroid
medication.
Most pharmacists felt it was important to counsel pa-
tients to improve adherence to medications and minimize
side effects.
“.. all the medications have side effects such as
don’t lie down to minimize the risk of side effects,
don’t drink coffee after you take Fosamax® and
must be compliant, what happen if miss dose, you
have to take it immediately, if too close, then skip
the previous one, don’t double the dose.” − 31-year-
old female
Screening using heel ultrasound
Of these, five independent community pharmacists
reported having hosted an ultrasound machine in
their pharmacies. Twelve pharmacists (10 from inde-
pendent pharmacies and 2 from chain pharmacies)
reported divergent views about the potential use of
heel ultrasound to screen for osteoporosis in their
practice. While some felt ultrasound screening
would promote public awareness about osteoporosis
and provide an opportunity for clients to ask phar-
macists about osteoporosis, others were doubtful
about the accuracy of the machine [in comparison
to dual-energy x-ray absorptiometry (DXA)] and
skeptical about the motive of the vendor. The par-
ticipants were aware that it would not be cost-
effective to purchase the ultrasound machine, and
that screening was ultimately linked to sales of
osteoporosis-related products such as calcium
supplements.
“… Bone scan on (the) ankle might not be that
accurate….. (Screening for osteoporosis using heel
ultrasound) is also a trigger point for them (clients) to
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discuss… what osteoporosis (is all about)…”-54-year-
old female
“…. we can actually utilize the machine, but double
edge is when suppliers come in they have something in
their mind. (If ) I (use) this machine, at the end of the
day I would like to have some sales…” – 30-year-old
male
Screening using osteoporosis questionnaires
One pharmacist from an independent pharmacy sug-
gested that screening for osteoporosis can be provided
in the community pharmacy. This can be performed by
calculating the client’s osteoporosis risk score based on
their age and weight.
“…. I will just tell (customers) what are the causes…
even actually osteoporosis, we can use and calculate
based on your age and weight, osteoporosis risk score,
you’ll tell them which category fall on.”—30-year-old
male
Despite the divergent views regarding the use of
heel ultrasound screening, the pharmacists agreed
that accessibility of community pharmacies was key
to screening and educating the public about
osteoporosis.
Barriers to providing osteoporosis disease state
management services
Eight themes emerged as barriers to the provision of
osteoporosis disease state management services by com-
munity pharmacists: (1) lack of public awareness, (2)
osteoporosis is a hidden disease, (3) high cost of osteo-
porosis medications, (4) lack of accurate and validated
screening tools for osteoporosis to be used in commu-
nity pharmacies, (5) lack of pharmacists’ knowledge (6)
lack of time to counsel about bone health, (7) lack of
collaboration between pharmacists and doctors due to
the lack of dispensing separation, and (8) lack of con-
tinuity of care.
Lack of public awareness
Currently, the main barrier faced by community phar-
macists was the lack of demand for osteoporosis preven-
tion from customers due to their lack of awareness
regarding osteoporosis.
“So far, we don’t really have (any) customer that comes
to the pharmacy and say “I want to prevent
osteoporosis,” but they come and say “I want to do
blood sugar screening” or the other like cholesterol, but
particularly for osteoporosis, nobody comes….”—46-
year-old female
The pharmacists perceived that the public’s lack of
awareness regarding osteoporosis may be due to a lack
of public campaigns regarding the severity of the osteo-
porosis, and its impact on health.
“… One of the reason for me, osteoporosis is
not something that I target is because there is
lack of public campaign… If there is a public
campaign, and then concurrent together (with)
pharmacies then we will be able to get the
numbers that we hope for…” - 51-year-old
female
Osteoporosis is a ‘hidden’ disease
The pharmacists also perceived that the public was not
aware of osteoporosis as it is a silent disease, unlike
osteoarthritis, which is associated with pain.
“I think because osteoporosis is actually a hidden kind
of health condition, because most people don’t know
they have osteopenia or osteoporosis until they do the
scan or if they have a fracture. Not like other
conditions sometimes you know they may have
symptoms”—39-year-old female
High cost of osteoporosis medication
Pharmacists also perceived that patients do not prioritize
osteoporosis as an important health condition. They per-
ceived that patients would rather spend their money on
medications for other health conditions such as
osteoarthritis.
“… sometimes it might be financial reason as well,
and you know they may wanted to use the money for
other most significant kind of condition than this,
because they don’t feel the pain, maybe they will
ignore until latest stage when it became serious.”
—39-year-old female
Osteoporosis medications can only be dispensed on
a doctor’s prescription. However, due to the lack of
dispensing separation in Malaysia, doctors are able to
dispense osteoporosis medication directly to patients.
As a result, community pharmacists seldom receive
prescriptions to dispense osteoporosis medications
from doctors. Consequently, five pharmacists reported
they did not stock osteoporosis medications in their
pharmacies.
“… (Medications) are quite expensive and there’s
no demand. I didn’t keep it (osteoporosis
medications) … unless the customer’s request and
she can provide prescription, then I’ll keep.”
—29-year-old male
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Lack of accurate and validated screening tools for
osteoporosis in community pharmacy
Twelve pharmacists (10 from independent pharmacies
and 2 from chain pharmacies) doubted the accuracy of
available screening tools. They felt heel ultrasound was
less accurate compared to a DXA scan, and preferred
their at-risk clients to be diagnosed and monitored via
DXA.
“…of course we know (ultrasound is) not 100%
accurate … for some customers who are more health
conscious they also know. So, I will advise them to go
to (the) hospital…”—43-year-old male
On the other hand, these pharmacists felt ultrasound
screening was important before discussing bone health.
This would require full-time access to a heel ultrasound
machine.
“… When we want to discuss about bone health,
sometimes they (customers) want to see some
proofs. So, we must do some sort of test … the
problem is we don’t have that machine…”
—42-year-old female
Pharmacists who had hosted ultrasound screening
tended to rely on vendors of ultrasound machines to
operate the machine, due to the high cost of that
service.
“…normally we just depended on the supplier to
provide us with the screening test, unless we buy the
machines for ourselves, then solve the problem…”
- 42-year-old female
Lack of pharmacists’ knowledge
Some pharmacists were not confident to talk about
osteoporosis with their customers because they did not
know much about osteoporosis and its management.
“I’m not that confident because I do not have a big
picture of what is the treatment, what is the
medicine, all the apparatus they are using, that one
is too much doctor thing for me. So, the
management part, I am not that familiar.”
- 37-year-old female
Lack of time to counsel about bone health
Time was a perceived limitation to the provision of
osteoporosis disease state management services; as such,
screening and counseling about bone health was not a
priority when the pharmacists were busy and clients pre-
sented with many health problems.
“…then for us to attend the customers, we have to
allocate special time to educate, to counsel the
customers, it’s not touch and go thing. It’s like
counseling anything about health. Time is the factor
that I said…”—42-year-old male
Additionally, this participant perceived that the
provision of osteoporosis disease state management ser-
vices was time consuming.
“…osteoporosis counseling involves many things such
as diet, exercise, exposure to sunlight, muscle mass,
body weight and so on. We (will need) to talk about
(this) for half an hour …”—43-year-old male
Lack of collaboration between pharmacists and doctors
The Malaysian healthcare system was not conducive
in supporting pharmacists to work with doctors in
providing patient care. Since both can dispense medi-
cations, there was a conflict of business interest be-
tween them.
“… That’s the problem with our healthcare system … I
think because both of us, doctors and pharmacists, can
dispense, both doctors and pharmacists are doing
business … conflict of interest … very seldom
community pharmacists get prescriptions (from
doctors).” - 42-year-old female
This indirectly affected the provision of osteoporosis
disease state management services by the pharmacists,
who require doctors’ support in the diagnosis and treat-
ment of osteoporosis as well as access to patients’ med-
ical records.
“… (osteoporosis) is quite familiar to me, but the
problem is about the diagnostic part, yet to be
confirmed by doctor… we might have some difficulties
in order to know what stages they are, whether they
have osteoporosis or not. To me, unless the clients are
actually eager to know, we can share more; otherwise
osteoporosis might be the part that everybody
missed.”—26-year-old male
Pharmacists, in general, felt it was difficult for them
to initiate a conversation about osteoporosis when
patients were not specifically referred to them for
counseling.
“… whenever customers come in complaining bone
pain, knee pain, that is the time we start to get
actively involve, usually as a pharmacist; (to initiate
a) management plan or counseling, we depend on
doctors’ diagnosis…”—33-year-old male
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Lack of continuity of care
According to one pharmacist, customers tended to
‘shop around’ for cheaper medicines. The resulting
lack of continuity of care posed a challenge to phar-
macists in providing effective osteoporosis care for
the patients.
“… I notice that we have regular customers, but
sometimes they shop around. They will go asking for
prices at different pharmacy, and then they will buy
this thing from this pharmacy because is about RM2
cheaper. So, they don’t actually stay at one pharmacy
usually.”—39-year-old female
Facilitators in the provision of osteoporosis disease state
management services
Six themes relating to facilitators were identified from
the data. These themes were further subdivided into
current facilitators and potential facilitators. Current
facilitators included continuing education support,
support from healthcare industry and availability of
suitable materials. Potential facilitators included cre-
ation of public health campaigns, inter-professional
collaboration and the provision of reimbursement
mechanisms.
Continuing education support on osteoporosis
Most pharmacists mentioned a need for support from
professional societies, such as the Malaysian Pharma-
ceutical Society, via education talks and seminars to im-
prove pharmacists’ knowledge on osteoporosis.
“…We need to keep on educating ourselves, because
there will be new knowledge on osteoporosis, new
supplements, new results for taking calcium, new
awareness. This support is very important for us, as a
pharmacist.”—42-year-old male
Support from healthcare industries
Pharmaceutical industries can support pharmacy ser-
vices by providing heel ultrasound machines to screen
for osteoporosis and the latest information update on
osteoporosis.
“…I think screening provided by certain
(pharmaceutical) company will encourage people to be
more aware of this problem in my area. I believe this
will trigger the awareness of osteoporosis.”—47-year-
old female
A simple and unbiased educational material regarding
osteoporosis for patients
Almost all pharmacists felt a simple and unbiased cus-
tomers’ education material regarding osteoporosis would
facilitate them to provide osteoporosis disease state
management services. The education materials could ei-
ther be a booklet or pamphlet produced by an independ-
ent body, and should contain unbiased information on
osteoporosis without product promotion.
“… if you have the booklet or anything about
osteoporosis from independent sources, we can just
give it to the customer when we are busy so they
can read it… if it is from the (medical) company,
definitely it will focus on their products.”—33-year-
old female
Public health campaigns on osteoporosis
Although the involvement of community pharmacists in
the provision of bone health was minimal, pharmacists
considered that they could play a more significant role
in health promotion and disease prevention, especially in
osteoporosis. The pharmacists felt that awareness about
osteoporosis should be promoted by the government
through media and health education activities so the
public would visit their pharmacists for advice about
bone health and osteoporosis.
“…the activities, we can go to school, where you can
reach the young generation or offices… where the
government can help us to penetrate the mass public.”
- 42-year-old male
Inter-professional collaboration practices
Pharmacists felt strengthening inter-professional ties
would improve the provision of osteoporosis disease
state management services by community pharmacists.
Ideally, the pharmacists would recommend high-risk pa-
tients to consult doctors for assessment, and the doctors
would refer the patients to the pharmacists for osteopor-
osis care.
“…basically we can’t work with one hand …
collaboration with (the clinic or private doctors) will
be quite a good one in the sense that you refer
(patients) for DXA scan and it’s a win-win situation
and (the doctors) get pay for their DXA and
subsequently whatever they have prescribed or not,
(patients) can always come back to the
pharmacist.”—30-year-old male
Government reimbursement for pharmacists’ services
Most pharmacists felt that if they were paid by the gov-
ernment for their time spent with their customers, they
would be more motivated to provide osteoporosis dis-
ease state management services.
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“Well, in my opinion … it is a good start … if we are
reimbursed for counseling … that will motivate us very
much.”—42-year-old male
Discussion
Findings from this limited sample suggest Malaysian
community pharmacists’ involvement in the provision
of osteoporosis disease state management services is
minimal. Our cohort appeared to be deeply rooted in
the traditional role of medication dispensing and
counseling, although they recognized the potential to
expand the boundaries of their work [35]. In this
study, only ad-hoc counseling, such as advice on
osteoporosis prevention, risk factors and lifestyle
modification, was practiced. This was due to a lack of
referral from doctors to pharmacists. Furthermore,
the public has a low level of awareness of osteopor-
osis, as it is a silent disease until fractures occur [36].
One of the proposed public health messages, and in-
deed a cornerstone of a pharmacist-initiated service
in this area, is the ‘latency’ of osteoporosis and the
need for prevention and early detection. These mes-
sages would be used to introduce service components
such as FRAX for screening. FRAX estimates fracture
risk within 10 years. It is a validated tool for pharma-
cists’ risk assessment for osteoporosis, and thus is
useful to educate patients about this condition. Com-
munity pharmacists also can play a more significant
clinical role in identifying drug-induced osteoporosis,
such as in corticosteroid users [37, 38]. Our partici-
pants also supported the role of community pharmacy
in the management of diagnosed osteoporosis through
counseling to optimize adherence to prescribed osteo-
porosis medicines and lifestyle changes.
Review of the literature indicates the prevalence of
osteoporosis in Asian countries is significant, and pre-
dicted to increase [39]. This points to a need for pub-
lic awareness that should be proactively addressed.
Our data suggest pharmacists associated clients’ lack
of awareness of this condition with inadequate public
health campaigns; this is surprising when raising pub-
lic awareness is indeed a role for pharmacists. This
may be achieved using posters and health promotion
initiatives in-store, and public health messages via the
media.
Notwithstanding this, our data are unable to deter-
mine whether clients’ apparent lack of awareness
about osteoporosis is a true lack of awareness, or
lack of awareness of pharmacists’ contribution in this
area. Clients may be aware of osteoporosis, but direct
their enquiries to another health professional or
search online for self-management options. In either
case, pharmacist-led health promotion should be ef-
fective in both raising the profile of pharmacists’ role
in osteoporosis management and public awareness.
Our participating pharmacists appeared amendable to
extending their services in this manner if more
osteoporosis training were provided for them to de-
velop competency. However, further research to ex-
plore the relevant stakeholders (such as doctors,
patients and policy makers) regarding pharmacy-led
osteoporosis disease state management services is
required.
Previous studies indicated osteoporosis screening in
community pharmacies has been well accepted by the
public and other health care partners [15, 17, 40].
However, the accuracy of current screening tools (heel
ultrasound and risk-assessment questionnaires) lacks
verification, at least according to our participants, and
would benefit from validation for their typical clients.
Available research suggests heel ultrasound screening
or a risk stratification algorithm (such as the fracture
risk assessment tool [FRAX®]) must be based on
device-specific cut-offs that are validated in the popu-
lations for which they are intended to be used [41].
The FRAX tool can be used to predict the probability
to sustain the fractures within the next 10 years with-
out the need to undergo a bone mineral density test.
It can be downloaded from the Internet and is easy
to use [42]. However, FRAX has not been validated in
Malaysia. It has only been validated among the Malay,
Chinese and Indian cohorts in Singapore. In the ab-
sence of a validated FRAX tool in Malaysia, use of
the Singaporean FRAX tool is considered acceptable
in Malaysia, due to similarities in their populations
[43]. In terms of risk-screening questionnaires, the
Osteoporosis Self-Assessment Tool for Asians is a
simple and cost-effective tool validated for Asian popu-
lations [44, 45], and is supported by evidence from a
trial in Thailand [22]. Regardless of evidence around
the accuracy of diagnostic tools, our participants recog-
nized the need to integrate screening measures and risk
assessment into their service protocol.
Similar to published studies [46–48], the adoption of
the disease state management services has been chal-
lenged by lack of knowledge, time and incentives, and
limited inter-professional collaboration. Identifying bar-
riers to pharmacists’ role transformation should be of
prime concern, to find solutions and inform the expan-
sion of these services. Pharmacists themselves can be
barriers to their expanding roles and implementation of
the disease state management services [49]. Our study
confirms published research reporting lack of knowledge
and time as intrinsic barriers to providing these services,
along with staff, equipment, and information technology
resources [50, 51]. Because of societal and normative ex-
pectations inherent in professional duty, pharmacists
may have been compelled to respond to professional
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duty items in a socially desirable manner [52]. Pharma-
cists perceive osteoporosis is not their main concern
compared to other conditions, such as diabetes and
hypertension, since there is less demand from customers
and lack of public campaign from government.
Interventions such as targeted educational programs on
osteoporosis using brochures or pamphlets may help
pharmacists to disseminate osteoporosis information to
clients [53].
A review of literature on the specific models for in-
ter-professional collaboration between doctors and
pharmacists found that trust and interdependency be-
tween doctors and pharmacists were critical determi-
nants to the collaboration process [54, 55]. In the
provision of osteoporosis disease state management,
the pharmacist is unable to definitively diagnose
osteoporosis, as this requires detailed clinical mea-
sures and judgement. Therefore, the pharmacist’s pre-
liminary assessment requires diagnostic confirmation
by the doctor. The pharmacist can then assist the
doctor to counsel patients on appropriate use of their
osteoporosis medications. In addition, pharmacists can
provide advice regarding non-pharmacological im-
provement of bone health, such as lifestyle and diet
modification [15]. However, due to the lack of dis-
pensing separation in Malaysia, the roles of the doc-
tors and pharmacists overlap, as both parties compete
to dispense medications to patients [23]. Hence, the
state of inter-professional collaboration between doc-
tors and pharmacists in Malaysia is minimal. Further
studies are required to ensure successful implementa-
tion of inter-professional osteoporosis disease state
management in Malaysia. Other factors, such as edu-
cation of policy makers, establishment of a reimburse-
ment system and finding ways to encourage
collaboration, should be addressed to achieve success-
ful implementation.
Strengths and limitations
The strength of this study is the application of quali-
tative methodology to collect rich, in-depth informa-
tion about experiences and perceptions of community
pharmacists on the provision of osteoporosis disease
state management services. While the data, as pre-
sented, do not identify the source as individual inter-
view or focus group, combining these methods was
perceived to add balance to the data. The focus
groups included study participants from heteroge-
neous settings, both independent and chain commu-
nity pharmacies; although there are advantages to
homogeneous groups [29], there are also benefits to
carefully-managed heterogeneous groups and the
richness of data that can be raised through interac-
tions in the group [56]. Mixed groups of pharmacy
owners and employees can foster idea stimulation
through inclusion of more diverse participants who
possess varying experiences and perspectives. There
were no perceptible differences in responses between
individual interview and focus group. However, in in-
dividual interviews, the facilitator had to probe the
participant more, whereas discussion flowed more
freely in the focus group discussions.
Findings from this sample may not be transferable
to all community pharmacists in other localities, as
there may be fewer opportunities for continuing edu-
cation and patient referral. Conversely, inter-
professional collaboration may be stronger in rural
areas. Because our participants self-identified for the
study, our data may reflect the views of those who
feel more strongly on the issues. Furthermore, our re-
cruitment strategy attracted involvement by pharma-
cists with and without experience in osteoporosis-
related services. This provided a broad, rather than
deep perspective to the issues. Another limitation of
our study was the small number of pharmacists inter-
viewed. In addition, there was no structured survey to
quantify the opinions and practices of Malaysian
community pharmacists regarding the provision of
osteoporosis disease state management. With the es-
tablishment of a model service in osteoporosis man-
agement, future research is recommended to focus on
reflections of the service providers.
Business-related financial issues were beyond the
scope of this study, and this is suggested for later re-
search in developing osteoporosis services or proposing
a structure for remuneration. Another possible limita-
tion is that participants may have given professionally-
desirable responses. To minimize this, the interviewers
highlighted their background and asked the respondents
to be open-minded to share their experiences and
opinions.
Conclusions
This study found that the involvement of Malaysian
community pharmacists in the provision of osteoporosis
disease state management was minimal due to lack of
public awareness and demand. Limited components of
osteoporosis management were practiced. Pharmacist
mainly counseled patients on intake of calcium and vita-
min D, diet and lifestyle modification. Ad hoc osteopor-
osis screening using heel ultrasound was seldom
conducted due to the unavailability of a suitable screen-
ing tool. Most identified FRAX as a suitable screening
tool. Development and trial of collaborative osteoporosis
disease state management services in community phar-
macy could be facilitated by training, support and
remuneration.
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Appendix 1
Table 2 The consolidated criteria for reporting qualitative studies (COREQ)
Guide questions/description Remarks Page no.
Domain 1: Research team and reflexivity
a). Personal Characteristics
1. Interviewer/ facilitator Which author/s conducted the interview
or focus group?
Three authors (PSML, CJN and JN) conducted
the in-depth interviews, while the focus group
discussions were conducted by PSML and CJN.
3
2. Credentials What were the researcher’s credentials?
E.g. PhD, MD






3. Occupation What was their occupation at the time
of the study?
The researchers’ occupations are as follows:
JN: a postgraduate student/pharmacist
PSML: academic / pharmacist
CJN: academic / family physician
LE: academic with Director of Research
responsibilities.
12






5. Experience and training What experience or training did the
researcher have?
JN attended a workshop on “how to conduct
qualitative research” and “how to use NViVo
software to analyse the data”.
PSLM, CJN and LE are experienced researchers in
qualitative studies and have collectively published
numerous qualitative research articles.
12
b). Relationship with participants
6. Relationship established Was a relationship established prior to
study commencement?
Only for the purposes of this research. n/a
7. Participant knowledge
of the interviewer
What did the participants know about
the researcher? e.g. personal goals, reasons
for doing the research
Some of the participants knew JN personally.
The remaining participants did not know any
of the researchers. However, all participants
knew that the interview was for research purposes.
n/a
8. Interviewer characteristics What characteristics were reported about
the interviewer/facilitator? e.g. Bias,
assumptions, reasons and interests in the
research topic
The characteristics of each author have been
reported in the section titled ‘Authors’ Information’.
12




What methodological orientation was stated
to underpin the study? e.g. grounded theory,
discourse analysis etc




11. Method of approach How were participants approached?
e.g. face-to-face, telephone, mail, email
An invitation was posted on online social
media (LinkedIn and Facebook). For those who
expressed interest to participate, an email was
then sent to confirm their interest, and to request
their telephone number. The participant information
sheet explaining the purpose of the study was then
emailed to these potential participants.
3
12. Sample size How many participants were in the study? 19 pharmacists were recruited. 4
13. Non-participation How many people refused to participate
or dropped out? Reasons?
Out of the 29 pharmacists approached, only 19
pharmacists completed the interviews (IDI = 9,
FGD = 10). The reason for not participating were
that they were busy.
4
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Table 2 The consolidated criteria for reporting qualitative studies (COREQ) (Continued)
c). Setting
14. Setting of data collection Where was the data collected? e.g. home,
clinic, workplace
Data were collected at the pharmacists’ home or
their workplace. Focus group discussions were
conducted in a private meeting room located
within a condominium residential area.
3
15. Presence of non-
participants
Was anyone else present besides the
participants and researchers?
No-one else was present besides the participants
and the researchers.
n/a
16. Description of sample What are the important characteristics
of the sample?
e.g. demographic data, date
The important characteristics of the samples were
their age, gender, education background, number
of years as a community pharmacist and whether




17. Interview guide Were questions, prompts, guides provided
by the authors? Was it pilot tested?
A topic guide was prepared (Table 1), and pilot
tested with 3 participants. Data from interviews
conducted in the pilot test were included in the
final analysis.
3
18. Repeat interviews Were repeat interviews carried out?
If yes, how many?
No repeat interviews were carried out. 3
19. Audio/visual recording Did the research use audio or visual
recording to collect the data?
Interviews were audio recorded. 3
20. Field notes Were field notes made during and/or
after the interview or focus group?
Field notes were made by JN after every interview
and focus group discussion. These field notes were
used to assist in the analysis of the transcribed audio
recordings.
3
21. Duration What was the duration of the interviews
or focus group?
The duration of the in-depth interviews ranged from
30 to 60 min, while the focus group discussions were
approximately 60 min.
3
22. Data saturation Was data saturation discussed? Data saturation was discussed in the methodology
section.
3
23. Transcripts returned Were transcripts returned to participants
for comment and/or correction?
The transcripts were not returned to participants for
comment or correction.
3
Domain 3: analysis and findings
a). Data analysis
24. Number of data coders How many data coders coded the data? Four authors worked in pairs (JN with CJN,
and PSML with LE).
3
25. Description of the coding
tree
Did authors provide a description of the
coding tree?
The two pairs of authors coded two interviews
line-by-line to develop an initial list of nodes,
and to develop a framework. This framework
was then used to code the next transcript.
Coding discrepancies were resolved by
discussion between representatives of the
pairs until consensus was reached. The lists of
nodes were used as the final coding framework
for the remaining transcripts. New nodes emerging
during coding were added to the list upon
consultation with the research team. The lists of
nodes were regrouped into larger categories as
themes emerged from the data. This systematic
approach to the analysis established an audit trail
from the transcripts of raw data through to the final
interpretation. Analysis was undertaken concurrently
with data collection to check for data saturation.
3
26. Derivation of themes Were themes identified in advance or
derived from the data
The themes were derived from the data during analysis. 4
27. Software What software, if applicable, was used
to manage the data?
NVivo 10 was used to manage the data. 3
28. Participant checking Did participants provide feedback on
the findings?
No, participants did not provide any feedback on
the findings.
n/a
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Facilitators in the provision of osteoporosis disease
state management services
Public health campaigns on osteoporosis 17
Continuing pharmacists’ education support on osteoporosis 13
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4
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